Sanders Pulls Ahead in Iowa, but a Tougher Clinton Aims to Even the Score
A new poll unveiled Thursday finds populist Bernie Sanders squeezing past Hillary Clinton for the first time as the preferred choice among likely Iowa caucus-goers.
The survey by Quinnipiac University shows the Vermont lawmaker receiving 41 percent, while Clinton garnered 40 percent. The figures put Sanders’ lead well within the poll’s 3.4 percent margin of error, but the numbers serve as another indication of how tight the Democratic primary has become, especially in Iowa where Clinton has long maintained an advantage.
Related: With Trump and Sanders Riding High, How Low Will Bush and Clinton Go?
The poll found another 12 percent of voters would support Vice President Joe Biden, who has yet to decide if he will enter the 2016 race. Former Maryland Governor Martin O’Malley received 3 percent, and the same number were undecided.
While many could view the survey as the latest sign Clinton’s campaign is flailing, the timing of the poll could prove crucial.
The study was conducted between August 27 and September 8. That was the same day the former secretary of State told ABC News that using a personal email account while in office was a mistake and that she is sorry for it.
Related: Hillary’s E-Mail Lapse ... Mistake ... Responsibility ... er, 'Apology'
“I do think I could have and should have done a better job answering questions earlier. I really didn’t perhaps appreciate the need to do that,” Clinton said. “What I had done was allowed, it was above board. But in retrospect, as I look back at it now, even though it was allowed, I should have used two accounts. One for personal, one for work-related emails. That was a mistake. I’m sorry about that. I take responsibility.”
The interview marked the first time she apologized for her unique email arrangement. Questions over Clinton’s use of a private server have dogged her candidacy since she entered the White House race earlier this year.
Republicans have used the controversy surrounding the server to paint Clinton as untrustworthy and unfit to serve in the White House.
Related: Clinton: Trump Is Bad for American Politics
Indeed, Thursday’s poll found that while Clinton is still liked among Democratic voters who believe she would make a good leader, Sanders fares better on the question of trustworthiness.
The Quinnipiac poll also closed before Clinton gave a muscular foreign policy speech at the Brookings Institution on, among other things, the Iran nuclear deal.
“We should anticipate that Iran will test the next president,” she said. “They'll want to see how far they can bend the rules.”
“That won't work if I'm in the White House. I'll hold the line against Iranian noncompliance,” Clinton added.
On the softer side of things, Clinton’s interview on “The Ellen DeGeneres Show” will air Thursday afternoon. The appearance will give her a chance to connect with female voters who are the backbone of her support.
Taken together, the various actions could put Clinton back atop the polls, at least in Iowa, and help her gain back ground she lost to Sanders in New Hampshire as well.
Top Reads From The Fiscal Times:
- House GOP Scores a Major Win in Obamacare Legal Challenge
- Hillary’s E-Mail Lapse ... Mistake ... Responsibility ... er, 'Apology'
- How Can You Tell There Are Russian Troops in Syria? Just Look for Some Soldier Selfies
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.